Randomized trial · people

Cagrilintide with semaglutide: 15.6% weight loss in type 2 diabetes

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In type 2 diabetes, adding cagrilintide to semaglutide gave more weight loss than either drug alone over 32 weeks, but its blood sugar edge over semaglutide alone was not clear.

Kind
Randomized trial
Studied in
People
Number studied
92
Published
2023
Journal
Lancet

What they tested

The team tested how well and how safely weekly cagrilintide combined with weekly semaglutide (called CagriSema) controls blood sugar in type 2 diabetes, compared with each drug alone.

How the study was done

A randomized, double-blind phase 2 trial (neither participants nor investigators knew who got what) in 92 adults with type 2 diabetes and a BMI, a weight-for-height score, of 27 kg/m2 or higher, all on metformin with or without an SGLT2 inhibitor, at 17 US sites. For 32 weeks, each person got a weekly shot under the skin of the combination, semaglutide alone or cagrilintide alone, each raised to 2.4 mg.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking cagrilintide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

HbA1c, a 3-month average of blood sugar, changed by -2.2 percentage points with the combination, -1.8 with semaglutide and -0.9 with cagrilintide. The combination beat cagrilintide alone on HbA1c (difference -1.3 percentage points) but not semaglutide alone (p=0.075). Body weight changed by -15.6% with the combination, -5.1% with semaglutide and -8.1% with cagrilintide, so the combination beat both single drugs, and time with blood sugar in the 3.9-10.0 mmol/L range rose from 45.9% to 88.9% on the combination. Side effects were reported by 68%, 71% and 80% of each group, mostly mild or moderate stomach and gut effects, with no level 2 or 3 hypoglycemia (low blood sugar) and no deaths.

What it doesn’t show

This was a small, 32-week phase 2 trial with no placebo arm, run only in US adults already taking metformin. It was funded by Novo Nordisk.

The paper

Frias et al. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023.

The compounds

More studies on Cagrilintide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking cagrilintide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo